The purpose of the trial is to evaluate the safety of microplasmin as well as its ability to open blocked arteries to the brain in patients with acute stroke when given into the artery at the site of the blockage.
Patients with angiographically documented acute intracranial vertebrobasilar artery occlusion presenting within 24 hours of neurological symptom onset will be enrolled into this open-label trial. During study drug administration, angiograms will be repeated at regular intervals to determine degree of clot lysis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
2
2 mg/kg, IA over 75 mins
Universitätsklinikum Erlangen
Erlangen, Germany
Universitatsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitätsklinikum des Saarlandes
Homburg/Saar, Germany
UKSH Campus Kiel
Kiel, Germany
Recanalization rate
Time frame: Day-7, Day-30 and Day-90
Clinical assessment
Time frame: Day-7, Day-30 and Day-90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ludwig-Maximilians-University Hospital
Munich, Germany
HSK Dr. Horst Schmidt Hospital
Wiesbaden, Germany
Sint Antonius Ziekenhuis
Nieuwegein, Netherlands